Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
PAPARASHLTH.NSthis companyParas Healthcare Limited	₹749.70	181.63×	20.15×	4.96×	27.81×	-146.2%	35.5%	10.9%	2.7%	11.1%	5.6%	-0.1%	3.53×	4.02×	1.52×	1.08×	0.0%	—	—	2	C
SUNPHARMA.NSSun Pharmaceutical Industries Limited	₹1,904.50	36.76×	5.05×	7.22×	22.63×	166.9%	55.7%	23.2%	19.6%	13.7%	11.5%	2.2%	0.06×	-0.38×	39.99×	2.82×	0.9%	5	11.54	4	A-
DIVISLAB.NSDivi's Laboratories Limited	₹11,565.50	61.47×	9.42×	14.95×	40.71×	-66.6%	43.2%	28.2%	24.3%	15.3%	12.5%	0.3%	0×	-0.03×	129.48×	5.43×	0.5%	3	—	2	C
TORNTPHARM.NSTorrent Pharmaceuticals Limited	₹4,780.00	66.02×	17.02×	10.22×	48.11×	34.1%	48.8%	24.8%	15.5%	25.8%	6.6%	1.4%	1.79×	4.27×	8.99×	1.13×	0.9%	2	4.78	3	B
LAURUSLABS.NSLaurus Labs Limited	₹2,454.00	60.27×	10.11×	7.86×	30.54×	-102.7%	40.2%	19.0%	13.0%	16.8%	11.3%	0.7%	0.48×	1.31×	7.6×	1.33×	0.2%	5	15.63	3	B
ZYDUSLIFE.NSZydus Lifesciences Limited	₹1,215.90	17.39×	3.23×	3.23×	11.53×	57.8%	51.7%	21.3%	18.6%	18.6%	9.7%	-1.4%	0.46×	1.29×	13.18×	1.27×	1.3%	4	—	2	B-
Peer median	—	60.27×	9.42×	7.86×	30.54×	34.1%	48.8%	23.2%	18.6%	16.8%	11.3%	0.7%	0.46×	1.29×	13.18×	1.33×	0.9%	4	11.54	3	—